Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Amneal Pharmaceuticals, Inc.
< Previous
1
2
3
Next >
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
March 25, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
March 01, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
February 27, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Participate at Upcoming Investor Conference
February 13, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
January 31, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
January 10, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023
January 04, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Announces Move to Nasdaq
December 15, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
December 07, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
December 01, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Participate at Upcoming Investor Conferences
November 03, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial Guidance
October 23, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio
October 12, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Report Third Quarter 2023 Results on November 7, 2023
October 05, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
September 06, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Receives First Product Approval in China
September 06, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
September 06, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India
August 29, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Participate at the 2023 Wells Fargo Healthcare Conference
August 25, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease
August 24, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Reports Second Quarter 2023 Financial Results
August 04, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics
July 26, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Report Second Quarter 2023 Results on August 4, 2023
July 06, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
July 03, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Receives U.S. FDA Complete Response Letter for IPX203
July 03, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals
June 15, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
June 14, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
Amneal to Participate at the 2023 Jefferies Healthcare Conference
May 24, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMRX
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.